Motixafortide acetate is under clinical development by BioLineRx and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Motixafortide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Motixafortide acetate overview

Motixafortide is under development for the treatment of metastatic pancreatic adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, adenocarcinoma of gastric or gastroesophageal junction, squamous cell carcinoma or adenocarcinoma of the esophagus and sickle cell disease. The drug candidate is administered through subcutaneous and intravenous route. BL-8040 is a short synthetic peptide which acts by targeting chemokine (C-X-C Motif) receptor 4 (CXCR4).

The drug candidate was also under development for hematological cancers including chronic myeloid leukemia, relapsed/refractory acute myeloid leukemia (AML) and squamous non-small cell lung cancer (first and third-line therapy), non-Hodgkin's lymphoma, neuroblastoma, melanoma, thrombocytopenia, aplastic anemia (AA), hypoplastic myelodysplastic syndrome, small cell lung cancer and acute respiratory distress syndrome (ARDS) secondary to COVID-19, acute myeloid leukemia and other respiratory viral infections.

BioLineRx overview

BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML) and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx‘s only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in-Maccabim-Re’ut, Israel.

For a complete picture of Motixafortide acetate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.